Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 26;24(19):14535.
doi: 10.3390/ijms241914535.

The Diagnosis and Management of Cutaneous Metastases from Melanoma

Cosimo Di Raimondo  1 , Flavia Lozzi  1 , Pier Paolo Di Domenico  1 , Elena Campione  1 , Luca Bianchi  1
Affiliations
Review

The Diagnosis and Management of Cutaneous Metastases from Melanoma

Cosimo Di Raimondo et al. Int J Mol Sci. .

Abstract

Melanoma is one of the deadliest skin tumors, accounting for almost 90% of skin cancer mortality. Although immune therapy and targeted therapy have dramatically changed the prognosis of metastatic melanoma, many patients experience disease progression despite the currently available new treatments. Skin metastases from melanoma represent a relatively common event as first sign of advanced disease or a sign of recurrence. Skin metastases are usually asymptomatic, although in advanced stages, they can present with ulceration, bleeding, and superinfection; furthermore, they can cause symptoms related to compression on nearby tissues. Treatments vary from simple surgery resections to topical or intralesional local injections, or a combination of these techniques with the most recent systemic immune or target therapies. New research and studies should focus on the pathogenesis and molecular mechanisms of the cutaneous metastases of melanoma in order to shed light on the mechanisms underlying the different behavior and prognoses of different patients.

Keywords: cutaneous metastases of melanoma; immunotherapy; melanoma; skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Garbe C., Amaral T., Peris K., Hauschild A., Arenberger P., Bastholt L., Bataille V., Del Marmol V., Dreno B., Fargnoli M.C., et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment—Update 2019. Eur. J. Cancer. 2020;126:159–177. doi: 10.1016/j.ejca.2019.11.015. - DOI - PubMed
    1. Whiteman D.C., Green A.C., Olsen C.M. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. J. Investig. Dermatol. 2016;136:1161–1171. doi: 10.1016/j.jid.2016.01.035. - DOI - PubMed
    1. Zbytek B., Carlson J.A., Granese J., Ross J., Mihm M.C., Jr., Slominski A. Current concepts of metastasis in melanoma. Expert Rev. Dermatol. 2008;3:569–585. doi: 10.1586/17469872.3.5.569. - DOI - PMC - PubMed
    1. Knight A., Karapetyan L., Kirkwood J.M. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers. 2023;15:1106. doi: 10.3390/cancers15041106. - DOI - PMC - PubMed
    1. Munhoz R.R., Postow M.A. Combinatorial Approaches to the Treatment of Advanced Melanoma. Hematol. Oncol. Clin. N. Am. 2021;35:145–158. doi: 10.1016/j.hoc.2020.08.015. - DOI - PMC - PubMed